Novartis’ Zelnorm is back…kind of
This article was originally published in Pharmaceutical Approvals Monthly
Novartis' 5-HT4 agonist will be available under a treatment investigational new drug protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women under 55, FDA announces July 27. Marketing of tegaserod was suspended in March after a pooled data analysis of 29 clinical trials revealed a higher chance of heart attack, stroke and worsening chest pain in patients treated with Zelnorm compared to those on placebo. "Novartis and the FDA are moving forward with this program because of requests from physicians and patients following the marketing suspension of Zelnorm in March 2007," Novartis said in a July 27 statement...
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.